Founded in 1999, the Company is focusing on the unmet needs of healthcare and life science industry. Aviva has pioneered cell-based platforms, which have led to an innovative product (SealChip™) which has become the industry standard for ion channel-focused drug discovery. The Company continues to leverage its expertise in cell-based assays by targeting new commercial applications which will benefit patients. Aviva is currently developing innovative rare cell enrichment technologies, particularly focused on circulating tumor cells (CTC), which will significantly advance the accuracy and sensitivity of cancer disease diagnosis and monitoring.
Based in San Diego, CA., AVIVA Biosciences Corporation develops enabling drug discovery and development technologies by combining biochips with cell biology. Key application areas include electrophysiology research, ion channel drug screening and rare-cell isolation.
In this interview, AZoNano visits the Graphene Engineering and Innovation Centre to talk with Mark Dickie, Composite Applications Manager, about how the GEIC is helping to take graphene composite innovation out of the lab and into the wider industry.
In this interview, we speak with Stanford's Gu Group about their newly developed metal nanocluster-based material that's advancing nanoscale 3D printing.
Professor Andre Nel
In this interview, AZoNano speaks with Professor Andre Nel about his involvement in innovative research describing the development of a 'glass bubble' nanocarrier that could help drug formulations access pancreatic cancer cells.
The MiniCapt® Pro is a remote microbial air sampler that is ideal for the pharmaceutical manufacturing industry.
This product profile outlines the NanoRacer High-Speed AFM from Bruker JPK.
NMR spectroscopy is a characterization technique that is extensively used by chemical researchers.